Want to join the conversation?
Biopharmaceutical companies $SPPI & Onxeo S.A. announced Phase 1 results of drug belinostat (Beleodaq) with the CHOP chemotherapy regimen as a first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL), a type of blood cancer. Study shows 86% response rate with 67% complete responses in patients with PTCL.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)